证券代码：688468 证券简称：科美诊断 公告编号：2025-016 科美诊断技术股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第一次临时股东会 召开地点：北京市海淀区永丰基地丰贤中路 7 号北科现代制造园孵化楼 B 座二层科美诊断技术股份有限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 5 日 至2025 年 9 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网 投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2025年9月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 ...

科美诊断技术股份有限公司信息披露管理制度 科美诊断技术股份有限公司 信息披露管理制度 （2025年8月） 第一章 总则 第一条 为规范科美诊断技术股份有限公司（以下简称"公司"）信息披 露管理行为，加强信息披露事务管理，保护投资者合法权益，根据《中华人民共 和国公司法》（以下简称"公司法"）《中华人民共和国证券法》（以下简称"证 券法"）《上市公司信息披露管理办法》《上市公司治理准则》《上海证券交易 所科创板股票上市规则》等有关法律法规的要求，结合《科美诊断技术股份有限 公司章程》（以下简称"公司章程"），制定本制度。 第二条 本制度所称"信息"是指可能对公司股票及其衍生品种的交易价 格、交易量产生较大影响或者对投资者的投资决策有较大影响的任何行为和事项 的有关信息及证券监督部门、上海证券交易所要求披露的其他信息（以下简称"重 大事项"、"重大事件"或"重大信息"）；所称"披露"是指在规定的时间内， 在上海证券交易所网站和中国证券监督管理委员会（以下简称"中国证监会"） 指定的媒体上，以规定的披露方式向社会公众公布前述的信息。 第三条 本制度所称"市值"是指交易前 10 个交易日收盘市值的算术平 均值。 第四 ...

科美诊断技术股份有限公司对外投资管理办法 科美诊断技术股份有限公司 对外投资管理办法 （2025 年 8 月） 第一章 总则 第一条 为了加强科美诊断技术股份有限公司（以下简称"公司"）对外投 资管理，保障公司对外投资的保值、增值，维护公司整体形象和投资人的利益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规及《科美诊 断技术股份有限公司章程》（以下简称"公司章程"）的有关规定，特制定本办法。 第二条 本办法所称对外投资是指本公司及控股子公司将货币资金、股权， 以及经评估后的实物、无形资产等可供支配的资源作价出资，对外进行各种形式 的投资活动。 第三条 建立本办法旨在建立有效的控制机制，对公司及控股子公司在组织 资源、资产、投资等经营运作过程中进行风险控制，保障资金运营的安全性和收 益性，提高公司的盈利能力和抗风险能力。 第四条 对外投资的原则： 1、必须遵守国家法律、法规的规定； 2、必须符合公司中长期发展规划和主营业务发展的要求； 3、必须坚持效益优先的原则。 第二章 对外投资的审批权限 5、 法律、法规规定的其他对外投资。 第七条 公司股东会、董事会为公司对外投资的决策机构，各自在其 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit in the latest quarter [1] - Kemei Diagnostics' stock closed at 8.32 yuan, down 4.26%, with a rolling PE ratio of 32.33 times and a total market capitalization of 3.337 billion yuan [1] - The company ranks 66th in the medical device industry, which has an average PE ratio of 55.76 times and a median of 39.14 times [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company obtained 64 new domestic and international authorized patents during the reporting period, showcasing its innovation capability and technical reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Core Viewpoint - Company Kemei Diagnostics has shown a significant increase in shareholder numbers and continues to innovate in the medical diagnostics field, despite a decline in revenue and net profit in the latest quarterly report [1]. Group 1: Company Performance - As of August 7, Kemei Diagnostics closed at 8.62 yuan, up 1.65%, with a rolling PE ratio of 33.50 times and a total market capitalization of 3.458 billion yuan [1]. - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Group 2: Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Kemei Diagnostics at the 68th position within the industry [1]. - The company’s static PE ratio is 27.21 times, and its price-to-book ratio is 2.42 times [2]. Group 3: Shareholder Information - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Group 4: Innovation and Patents - During the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capabilities and technical reserves [1].

科美诊断最新一期业绩显示，截至2025一季报，公司营业总收入8130.01万元、同比减少27.01%，归属 净利润1454.28万元，同比减少62.12%，扣非净利润1113.14万元，同比减少68.00%，流动比率7.125、速 动比率6.374、资产负债率21.19%。 天眼查商业履历信息显示，科美诊断技术股份有限公司，成立于2007年，位于北京市，是一家以从事专 业技术服务业为主的企业。企业注册资本40110.8万人民币，实缴资本36000万人民币。公司法定代表人 为李临。 通过天眼查大数据分析，科美诊断技术股份有限公司共对外投资了3家企业，参与招投标项目76次，知 识产权方面有商标信息360条，专利信息489条，此外企业还拥有行政许可110个。 来源：金融界 金融界消息 截至2025年8月7日收盘，科美诊断（688468）报收于8.62元，上涨1.65%，换手率4.38%， 成交量17.57万手，成交金额1.54亿元。 资金流向方面，今日主力资金净流入1699.23万元，占比成交额11.04%。其中，超大单净流入756.77万 元、占成交额4.92%，大单净流入942.46万元、占成交额6.13%，中 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit while showcasing its innovation capabilities through patent acquisitions [1][2]. Group 2 - Kemei Diagnostics closed at 8.6 yuan, down 1.83%, with a rolling PE ratio of 33.42 times and a total market value of 3.45 billion yuan [1]. - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Kemei Diagnostics at the 69th position in the industry ranking [1]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1]. - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products being the LiCA and CC series [1]. - During the reporting period, the company obtained 64 new domestic and international authorized patents, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, reflecting its growing innovation capability and technical reserves [1]. - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, indicating a significant drop in its stock price and earnings compared to industry averages [1][2] - Kemei Diagnostics closed at 8.76 yuan, with a PE ratio of 34.04, marking a new low in 367 days, and a total market capitalization of 3.514 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Kemei Diagnostics at the 68th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average of 27,600 shares per shareholder [1] - The company specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5 million yuan, down 62.12%, with a gross margin of 66.88% [1]

Group 1 - The core viewpoint of the news is that Kemei Diagnostics has experienced a significant increase in stock price, reaching 8.49 yuan, up 6.66%, with a rolling PE ratio of 32.99, marking a new low in 113 days [1] - The total market capitalization of Kemei Diagnostics is 3.405 billion yuan, while the average PE ratio in the medical device industry is 53.65, and the median is 37.22, placing Kemei Diagnostics at the 68th position in the industry ranking [1] - As of March 31, 2025, Kemei Diagnostics has 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with major products including the LiCA series and CC series [1] - The company has obtained 64 new domestic and international authorized patents during the reporting period, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

金融界消息 截至2025年8月1日收盘，科美诊断（688468）报收于8.49元，上涨6.66%，换手率6.54%， 成交量26.23万手，成交金额2.20亿元。 天眼查商业履历信息显示，科美诊断技术股份有限公司，成立于2007年，位于北京市，是一家以从事专 业技术服务业为主的企业。企业注册资本40110.8万人民币，实缴资本36000万人民币。公司法定代表人 为李临。 科美诊断最新一期业绩显示，截至2025一季报，公司营业总收入8130.01万元、同比减少27.01%，归属 净利润1454.28万元，同比减少62.12%，扣非净利润1113.14万元，同比减少68.00%，流动比率7.125、速 动比率6.374、资产负债率21.19%。 来源：金融界 资金流向方面，今日主力资金净流入2669.99万元，占比成交额12.15%。其中，超大单净流入35.50万 元、占成交额0.16%，大单净流入2634.49万元、占成交额11.99%，中单净流出流出811.85万元、占成交 额3.69%，小单净流出1858.14万元、占成交额8.46%。 通过天眼查大数据分析，科美诊断技术股份有限公司共对外投资了3家企业，参 ...